Construction of a high-EGFR expression cell line and its biological properties comparing with A431 cell

African Journal of Biotechnology

Volumn 9, Issue 30, 2010, Pages 4674-4680

  Zhang, Yanmin ^a   Li, Xu ^a   Xu, Xuemei ^a   Luo, Wen Juan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

A431 cell line and taspine; Drug targeted screening; High EGFR expression

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; SUNITINIB; TASPINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL GROWTH; CELL LINE; CELL STRAIN A431; CELL STRAIN HEK293; CELLULAR MEMBRANE CHROMATOGRAPHY; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

EID: 77956117952     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM (2004). Mechanisms of resistance to erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest Surg. 8: 960-969.
2. Arteaga CL (2002). Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl. 4): 31-39.
3. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L (2001). Studies leading to the identification of ZD1839(IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11:1911-1914.
4. Baselga J, Averbuch SD (2000). ZD1839('Iressa')as an anticancer agent Drugs, 60(suppl.1): 33-40.
5. Cao C, Lu S, Sowa A, Kivlin R, Amaral A, Chu W, Yang H, Di W, Wan YS (2008). Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Letters, 266(2): 249-262.
6. Chang GC, Yu CTR, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ, Hsu SL (2008). An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur. J. Pharmacol. 600: 37-44.
7. Fischel JL, Formento P, Milano G (2005). Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Br. J. Cancer. 92:1063-1068.
8. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G (2003). Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9:2316-2326.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
10. Newby JC, Johnston SR, Smith IE, Dowsett M (1997). Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer, Clin. Cancer Res. 3:1643-1651.
11. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004). Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature, 429(6992): 629-635.
12. Okuse K, Hall MM, Baker MD, Poon WYL, Kong H, Chao MV, Wood JN (2002). Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature, 417(6889): 653-656
13. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Sci. 304: 1497-1500.
14. Pinaki RD, Amit MZ (2007). Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254(2):165-177.
15. Raben DM, Cunningham DD (1985). Effects of EGF and thrombin on inositol-containing phospholipids of cultured fibroblasts: stimulation of phosphatidylinositol synthesis by thrombin but not EGF. J. Cell Physiol. 125:582-590.
16. Sordella R, Bell DW, Haber DA, Settleman J (2004). Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Sci. 305:1163-1167.
17. Yarden Y, Mark X, Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:127-137.